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Toll-like receptors (TLRs) are transmembrane proteins acting mainly as sensors of microbial components. Triggering TLRs results
in increased expression of multiple inﬂammatory genes, which then play a protective role against infection. However, aberrant
activation of TLR signaling has a signiﬁcant impact on the onset of cancer, allergy, sepsis and autoimmunity. Various adaptor
proteins, including MyD88, IRAKs, TIRAP, TRIF, and TRAM, are involved in speciﬁc TLR signaling pathways. This article reviews
the role of these molecules in TLR signaling, and discusses the impact of this pathway on various disease scenarios. Given their
important role in infectious and non-infectious disease settings, TLRs and their signaling pathways emerge as attractive targets for
therapeutics.
1.Introduction—TheTLRPathway
The immune system consists of two closely related systems
known as the innate and adaptive immune systems. The
adaptive immune system responds to speciﬁc “nonself”
antigens and generates immunological memory. In contrast,
the innate immune system provides an immediate ﬁrst line
of defense against a diverse repertoire of invading microbial
pathogens.Thekeycomponentsofinnateimmunity,cognate
pattern recognition receptors (PRRs), are considered to
act as sentinels against both invading organisms bear-
ing pathogen-associated molecular patterns (PAMPs) and
damage-associated molecular pattern molecules (DAMPs).
Toll-like receptors (TLRs) are good examples of these recep-
tors [1]. Because of their wide-ranging impact upon both
innate and adaptive immunity in several disease settings,
TLRs and their signaling pathways emerge as attractive
therapeutictargets.Thisreviewsummarizesthemainplayers
in innate immune signaling and highlights possible drug
targets in various disease settings.
Innate immune responses are triggered mainly by a
spectrum of “danger” signals referred to as PAMPs and
DAMPs. PAMPs are exogenous molecules derived from both
pathogenic and nonpathogenic microbes. In contrast, the
vast majority of DAMPs are endogenous molecules released
from dying host cells molecules upon cellular stress or tissue
damage [2–5] .T h eT L R sa r eaf a m i l yo fe v o l u t i o n a r i l y
conserved PRRs that play a key role in sensing the microbial
world. Diﬀerent TLR members are reported to recognize and
respond to diﬀerent PAMPs and some endogenous DAMPs
[6], thus initiating innate immune responses and priming
antigen-speciﬁc adaptive immunity, both in infectious and
noninfectious disease scenarios.
TLRs are type I transmembrane glycoproteins which
are structurally characterized by extracellular leucine-rich
repeats (LPRs) and Toll/IL-1 receptor (TIR) signaling
domains. The ﬁrst TLR to be characterized was TLR4 and
the family has now been expanded to include 10 members
in humans and 12 members in mice [2, 3]. Apart from
the highly conserved pathogenic components of bacteria,
viruses, fungi, and parasites, TLRs can also be activated by
endogenous ligands such as chromatin-IgG complexes [4].
Various TIR domain-containing adaptors such as MyD88,
TIRAP, TRIF, and TRAM become engaged or activated upon2 Mediators of Inﬂammation
ligation of TLRs, as diagrammed in Figure 1. TLR1, TLR2,
TLR4, and TLR6 recruit TIRAP, which serves as an adaptor
between the TIR domain of TLRs and MyD88, while TLR5,
TLR7,TLR9,andTLR11canrecruitMyD88directly.Binding
of TLR3 and TLR4 ligands results in the recruitment of
TRIF. However, the recruitment of TRIF by TLR4 needs
the participation of TRAM (Figure 1). The recruitment
of these adaptors triggers a cascade of signaling molecules
and ultimately activates the transcription factors, NF-κB
and IRFs (Figure 1). These transcription factors induce
the expression of various inﬂammatory cytokines, type I
interferons, and chemokines. NF-κB is a central regulator of
immune responses involved in cell proliferation and survival
and induces the expression of many cytokine and chemokine
genes including IL-2, IL-6, IL-12, MCP-1, and TNF-α [1].
Except forTLR3, allTLR ligation events recruit the adap-
tor MyD88, followed by the IRAK family of protein kinases,
leading to the activation of TRAF6. TRAF6 induces the
activation of TAK1 through K63-linked polyubiquitination.
NF-κB or AP-1 is then activated by the IKK complex or
MAP kinases, respectively (Figure 1). On the other hand,
TLR3 initiates a TRIF-dependent pathway that dictates the
expression of inﬂammatory cytokines and type I IFNs via
two independent pathways. The N-terminal domain of TRIF
interacts with TRAF6 while the C-terminal domain of TRIF
interacts with RIP1 and activates TAK1, both of which can
activate NF-κB, resulting in the expression of inﬂammatory
cytokines [5]. TLR3 engagement induces the expression
of type I IFNs via IRF3 [7]. IRF3 is phosphorylated and
activated by the IKK-related kinase, TBK1, facilitated by the
recruitment of TRAF3 [8]. TLR7 and TLR9 engagement
induces the secretion of inﬂammatory cytokines through
the activation of NF-κB via MyD88. However, TLR7 and
TLR9 can also induce the expression of type I IFNs through
the activation of IRF7, which is phosphorylated by IRAK1,
IRAK4, or IKKα, and then translocated to the nucleus where
it induces the transcription of IFN-α (Figure 1)[ 9].
AsisevidentfromFigure1,theIRAKfamilyofmolecules
plays a pivotal role in mediating almost all TLR-mediated
functions. The IRAK family has four members: IRAK1,
IRAK2, IRAKM, and IRAK4. All IRAK family members
contain an amino-terminal death domain and a serine-
threonine kinase domain. IRAK4 is known to be essential for
TLR-IL-1R-mediated cellular responses. After TLR ligation,
IRAK4 phosphorylates IRAK1 [10]. The IRAK1 gene is
composed of 14 exons and is located on the X chromosome
[11]. IRAK1 is the ﬁrst member of this kinase family that
was identiﬁed as a key component of the IL-1R signaling
pathway and plays a speciﬁc and essential role in IFN-
α induction downstream of TLR7 and TLR9 engagement.
IRAK1 deﬁciency abrogates the production of IFN-α,I L -
6, IL-12, and TNF-α when stimulated with TLR7 or TLR9
ligands [12, 13].
2.TLR SignalingandDisease
TLRs constitute a primary defense mechanism in both infec-
tions and some noninfectious disease settings in mammals.
Activation of TLRs and the MyD88 signaling pathway plays
a protective role during infection with several pathogens,
including protozoan parasites [14] and pyogenic bacteria
[15]. Patients with autosomal recessive MyD88 deﬁciency
have been reported to suﬀer from life-threatening, often
recurrent pyogenic bacterial infections. Interestingly, how-
ever,theirclinicalstatusimprovedinlaterlife,alludingtothe
compensatory eﬀect of adaptive immunity [15]. Consistent
with their vital role in ﬁghting infections, downregulation
of TLR-related molecules or signaling has been associated
with sepsis and autoimmune disease, as discussed below.
On the other hand, upregulation of these molecules has
been linked to cancer, allergy, other autoimmune diseases
and immune abnormalities in HIV [16, 17], as detailed
below.
Sepsis is a serious medical condition that is characterized
by a systemic inﬂammatory state and the presence of a
known or suspected infection, which can lead to rapid tissue
damage. The recognition of LPS by TLR4 during an acute
Gram-negative bacterial infection plays a key role in the
pathogenesis of sepsis. Weighardt and colleagues found that
MyD88-deﬁcientmicewereprotectedfromdevelopingsepsis
in a polymicrobial septic peritonitis disease model [18]. In
the IRAK4-deﬁcient model, it was found that mice were
severely impaired in their responses to viral and bacterial
challenge [19]. Recently, Ferwerda and coworkers reported
that polymorphisms in human Mal/TIRAP allele showed
association to the pathogenesis of sepsis [20]. On the other
hand, others have provided proof that Mkp-1, a key negative
regulator of TLR-induced inﬂammation, plays a critical role
in the inhibition of innate immunity during Gram-negative
bacteria sepsis [21, 22]. MyD88 also plays a pivotal role
in infectious diseases, as demonstrated by Naiki et al. in
another model of bacterial pneumonia [23]. Collectively,
these studies revealed that the TLR pathway plays a pivotal
role in the pathogenesis and control of sepsis.
The importance of TLR expression and function in
cancercellsanditsassociationwithtumorigenesisandtumor
progressionhaverecentlybeenexamined.TLR4expressionis
linked to several cancers such as gastric cancer and human
epithelial ovarian cancer. Huang et al. reported that TLR4
was expressed in murine tumor cells and that the activation
of TLR4 in these cells by LPS induced the expression of
various soluble factors including interleukin-6, inducible
nitric oxide synthase, interleukin-12, B7-H1, and B7-H2 and
rendered tumor cells resistant to CTL attack. The factors in
LPS-stimulatedtumorcellsupernatantsalsohadthecapacity
to inhibit T cell proliferation and natural killer cell activity
[24]. Kelly et al., have reported that human epithelial ovarian
cancer cells (EOC) ubiquitously express TLR4 and that the
proliferation of EOC cells or enhanced cytokine/chemokine
production by EOC cells was dependent upon expression
of MyD88 [25]. MyD88-dependent signaling controls the
expression of several key modiﬁer genes in tumorigenesis
and has a critical role in both spontaneous and carcinogen-
induced tumor development [26]. Others have reported that
gene expression diﬀerences in the TLR gene cluster (TLR10-
TLR1-TLR6) were associated with a statistically signiﬁcant
reduced risk of prostate cancer [27].Mediators of Inﬂammation 3
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Figure 1: The TLR signaling pathway and downstream eﬀector molecules. Depicted are key TLR molecules, their signaling adaptors and
downstream mediators that are essential for TLR signaling and function. The speciﬁc molecules in this network that are presently being
interrogated as potential therapeutic targets include TLR7/9, MyD88 and IRAK1/4, as discussed in the text.
Functionally active TLR9 is also known to be expressed
on several human tumors, including lung cancer, Burkitt
lymphoma, cervical neoplasia, breast cancer, and prostate
cancer [28–32]. Although the role of TLR9 in the develop-
ment of these cancers is not fully understood, TLR9 appears
to be playing an important modulatory role in several of
these tumors [32–35]. Based on these ﬁndings, several TLR9
agonists, including CpG oligonucleotides, are currently in
development for the treatment of cancer. These agents have
the capacity to upregulate the innate immune response, as
well as a humoral immune response against the tumor,
as reviewed elsewhere [36].Thus, CpG-ODN can activate
plasmacytoid DCs (pDCs) to secrete type I interferon (IFN)
and also promote the expression of costimulatory molecules
such as CD80 and CD86, on the DCs as well as on TLR9-
expressing tumors. This can then lead to the secretion
of various cytokines/chemokines, and also activate natural
killer (NK) cells, TH1 cells, and cytotoxic T lymphocytes
(CTLs). Engaging these diverse mechanisms, TLR9 agonists
have been found to be therapeutically eﬀective in various
cancer trials [36–40].
The link between TLR and autoimmune diseases has
also become apparent. It was reported that inhibition of
TLR4 suppressed the severity of experimental arthritis and
resulted in lower IL-1 expression in arthritic joints [41].
Roelofs found that a TLR4 variant (Asp299Gly) could reduce
its potency to mediate signaling in rheumatoid arthritis
patients [42]. A TLR2 R753Q polymorphism has been
reported to be more prevalent among reactive arthritis
patients [43]. Likewise, polymorphisms in TLR2 and TLR4
may also be important in the pathogenesis of SLE in both
patients [44]a n dm o u s em o d e l s[ 45]. Moreover, TLR7 has
been suggested to be functionally involved in autoantibody
production, and hence closely linked to the pathogenesis of
SLE [46]. Indeed, the translocation of the X-linked TLR7
genetotheY-chromosomehasbeendocumentedtofacilitate
the development of fatal lupus in mice with numerous
immunological aberrations, hence constituting disease genes
for murine lupus [47, 48].
The impact of MyD88 and IRAK1 deﬁciency on
autoimmunity has been quite well documented. Harada
and coworkers reported that MyD88-deﬁciency protected
MRL/lpr mice from the development of autoimmune
nephritis, marked by lower levels of serum anti-double-
stranded DNA (anti-dsDNA) antibodies and reduced
cytokines, including interferon-α, interleukin-12, IL-6, and
IFN-γ [49]. Similarly it was reported that MyD88-deﬁcient
mice were completely resistant to experimental autoimmune
uveitis (EAU) and had reduced Th1, but not Th2, responses
upon immunization with retinal Ag [50]. In all of the above
studies of sepsis, cancer, and autoimmunity, a caveat should
be kept in mind when interpreting ﬁndings derived using
MyD88-deﬁcientmice.IthasbeendocumentedthatMyD88-
deﬁcient mice show a loss of IL-1- and IL-18-mediated4 Mediators of Inﬂammation
functionsindicatingthatthephenotypesobservedinMyd88-
deﬁcient mice might arise in part because of defects in
signaling downstream of the IL-1 and Il-18 receptors [51].
Autoimmunity also appears to be contingent upon the
expression of another TLR signaling molecule, IRAK1. It
has been reported that IRAK1-deﬁcient mice are resis-
tant to experimental autoimmune encephalomyelitis (EAE),
exhibiting little or no inﬂammation in the central nervous
system [52]. IRAK1-deﬁcient mice exhibited impaired Th1
cell development with minimal IFN-γ secretion during dis-
ease induction following immunization with myelin antigen
[52]. The authors suggested that the mechanism underlying
this observation might relate to an impaired adjuvant eﬀect
on antigen presenting cells as a result of suboptimal TLR
activation. Our recent study has revealed that the IRAK1
gene was highly associated with both adult- and childhood-
onset SLE [53]. Using the IRAK1-deﬁcient mice, we found
that in mice bearing the lupus susceptibility loci, Sle1 or Sle3,
IRAK1deﬁciencyabrogatedalllupus-associatedphenotypes,
including IgM and IgG autoantibodies, lymphocytic activa-
tion, and renal disease. In addition, the absence of IRAK1
reversed the dendritic cell “hyperactivity” associated with
lupus [53].
Heme oxygenase-1 (HO-1), a key cytoprotective, antiox-
idant, and anti-inﬂammatory molecule, was reported to
be involved in the activation of IRF3 after TLR3 or
TLR4 stimulation, or viral infection. HO-1 is necessary
for the expression of primary IRF3 target genes encoding
RANTES, IP-10, and MCP-1. In the experimental autoim-
mune encephalomyelitis model, mice with myeloid-speciﬁc
HO-1 deﬁciency developed severe disease correlating with
hyperactive antigen-presenting cells, enhanced inﬁltration of
Th17cells,andnonregressingmyelin-speciﬁcTcellreactivity
[54]. Interestingly, IFN-β could alleviate these defects. The
overproduction of IFN-α and IFN-α-dependent genes, such
as IRF5, are additional factors that play a key role in the
pathogenesis systemic lupus erythematosus [42].
3. PotentialTherapeuticTargets inthe TLR
SignalingPathway
Since the bulk of the data suggests that the TLR pathway
plays a key role in multiple pathogenic processes, the
targeting of either the TLRs themselves or the signals they
generate is of great interest, as reviewed by O’Neill [55].
As MyD88 is clearly involved in infectious disease, cancer,
and autoimmune diseases, it is obviously an attractive
target for intervention in these diseases. Loiarro et al.
have reported a MyD88 inhibitor ST2825, a heptapeptide
analog speciﬁcally designed to inhibit MyD88 dimerization,
which could control TLR mediated inﬂammatory responses
[56]. ST2825 is reported to inhibit MyD88 dimerization
in co-immunoprecipitation experiments, and is speciﬁc
for homodimerization of the TIR domains but does not
aﬀect homodimerization of the death domains. They tested
ST2825 in experimental animal models of autoimmune,
and inﬂammatory diseases, such as lupus, inﬂammatory
bowel disease, and multiple sclerosis, and found that ST2825
could interfere with the recruitment of IRAK1 and IRAK4
by MyD88, resulting in the inhibition of IL-1β-mediated
activation of NF-κB and IL-6. They also observed that
ST2825 suppressed B cell proliferation and diﬀerentiation
into plasma cells in response to CpG-induced activation
of TLR9. Bartfai et al. have also designed a low molec-
ular weight MyD88 mimic, “Compound 4a”, which could
interfere with the interaction between MyD88 and IL-1R
at the TIR domains [57]. Compound 4a inhibited IL-1β-
induced phosphorylation of the mitogen-activated protein
kinase p38 in EL4 thymoma cells and in freshly isolated
murine lymphocytes, and signiﬁcantly attenuated IL-1β-
induced fever response in vivo. These data suggest that
MyD88 might be a potential target for pharmaceutical usage
in several disease settings where increased TLR signaling is
driving disease pathogenesis.
Modulation of another signaling molecule in the TLR
pathway, IRAK4, has also been suggested to be an attractive
therapeutic approach for the treatment of cancer, autoim-
mune and inﬂammatory diseases. A series of small-molecule
compounds that inhibit IRAK4 has been developed by
Wang et al. [58]. However, the eﬀectiveness of these IRAK4
inhibitors in vitro and in vivo remains to be documented.
Another group has reported that a dual inhibitor of IRAK1
and IRAK4 (RO0884) could eﬃciently inhibit both IL-1β
and TNF-α induced p38 MAP kinase, c-Jun N-terminal
kinase activation, and IL-6 production in human cells [59].
Through silencing IRAK1 or IRAK4 gene by siRNA, they
also found that IRAK4 was essential for response to IL-
1β but not to TNF-α, whereas IRAK1 was essential for
cellular responses to TNF-α but not IL-1β. These data
suggested that inhibition of both IRAK1 and IRAK4 kinases
would be necessary to block proinﬂammatory cytokine
production [59]. Collectively, these ﬁndings raise hope that
IRAK1/IRAK4 inhibitors may be of therapeutic beneﬁt in
autoimmune and inﬂammatory diseases.
Administration of synthetic oligodeoxynucleotides with
immunoregulatory sequences (IRS) that speciﬁcally inhibit
both TLR7 and TLR9 signaling (IRS 954) has been shown
to decrease the production of IFN-α by human PDCs
after stimulation with DNA or RNA viruses [60]. It has
been reported that (NZB×NZW) F1 mice showed decreased
serum levels of antinuclear autoantibodies, proteinuria, and
glomerulonephritis, with increased survival upon IRS 954
treatment [61]. Another oligodeoxynucleotides inhibitor
IRS 661, which is speciﬁc to TLR7, had the capacity to
signiﬁcantly reduce disease in MRL/lpr mice, particularly
the weights of spleen and lymph nodes and serum levels
of TNF-α as compared with saline-treated control [62].
Injection of IRS 661 but not IRS 954 can signiﬁcantly
decreased anti-dsDNA and anti-Sm antibodies in lupus-
prone mice. Most interestingly, both IRS 661 and IRS 954
could be detected in the kidneys and were found to be
taken up by glomerular cells, tubular epithelial cells, and
intrarenal macrophages. The mRNA levels of inﬂammatory
chemokines CCL2 and CCL5 and their respective chemokine
receptors CCR2 and CCR5 were also decreased in the
kidneys. Consistent with these ﬁndings, the activity and
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661- or IRS 954-treated mice were also reduced signiﬁcantly
[62]. Besides lupus, these inhibitors have also shown eﬃcacy
in other autoimmune diseases including arthritis and mul-
tiple sclerosis [63–65]. Based on a recent report suggesting
that SLE in patients is also contingent upon TLR signaling
[66], antagonists of this pathway are expected to confer
therapeutic beneﬁt in patients as well.
4. Conclusion
TLR molecules and their downstream signaling pathways
play a critical role in activating innate immune cells and
selected cell types in the adaptive arm of the immune system.
Given that this pathway is aberrantly expressed or activated
in several diseases, this axis constitutes an attractive target
for therapeutic intervention. There is mounting evidence
documenting that the crippling of this pathway at the
level of TLR, MyD88, or IRAK1/4 may confer therapeutic
eﬃcacy in autoimmunity and auto-inﬂammatory diseases.
On the other hand, the total crippling of these pathways may
compromise immune defense against invading infections
and immune surveillance against cancers. In fact, agonists
of these pathways appear to be useful in some of these
disease settings. Hence there is a need to carefully select the
therapeutic target in the TLR signaling cascade, and closely
regulate the degree of pathway activity so as to attain the
desired therapeutic end-point. Like many other molecules
in biology, the TLR signaling axis emerges as yet another
“double-edged sword”.
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